Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.71 |
| ▸ | CA2 | P00918 | 15/20 | 0.71 |
| ▸ | CA9 | Q16790 | 15/20 | 0.71 |
| ▸ | CA12 | O43570 | 2/20 | 0.63 |
| ▸ | CA3 | P07451 | 2/20 | 0.63 |
| ▸ | CA6 | P23280 | 2/20 | 0.63 |
| ▸ | CA5A | P35218 | 2/20 | 0.63 |
| ▸ | CA7 | P43166 | 2/20 | 0.63 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.63 |
| ▸ | CA4 | P22748 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | LPL | P06858 | 4/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.50 |
| ▸ | F11 | P03951 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21693475 | 0.85 | CA1 (0.57) | CA1CA2CA9CA12CA3 | |
| SCHEMBL10904 | 0.83 | CA1 (0.56) | CA1CA2CA9CA12CA3 | |
| SCHEMBL23758975 | 0.81 | CA1 (0.54) | CA1CA2CA9CA12CA3 | |
| SCHEMBL15793751 | 0.80 | CA1 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL16797009 | 0.80 | CA1 (0.53) | CA1CA2CA9CA12CA3 | |
| SCHEMBL182781 | 0.80 | CA2 (0.60) | CA1CA2CA9CA12CA3 | |
| SCHEMBL228212 | 0.79 | LPL (0.71) | CA1CA2CA9CA12CA3 | |
| SCHEMBL16817 | 0.79 | LPL (0.61) | CA1CA2CA9CA12CA3 | |
| SCHEMBL557918 | 0.79 | CA1 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL30549648 | 0.79 | CA1 (0.51) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| CN-1551869-A | Novel compound | — | 2004-12-01 | — | — | CN | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| US-6559310-B2 | Reacting a halogen aromatic derivative at a coupling position with a diboron derivative in the presence of a Group VIII metal catalyst and a suitable base for covalently coupling organic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-05-06 | — | — | US | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20020193604-A1 | Aryl borates | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-12-19 | — | — | US | claimed |
| US-20020032339-A1 | ARYL BORATES | BORON MOLECULAR LIMITED (AU) | 2002-03-14 | — | — | US | claimed |
| EP-4565562-B1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2026-02-12 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBVIE INC. | 2005-02-17 | — | — | US | disclosed |
| CN-1551869-A | Novel compound | — | 2004-12-01 | — | — | CN | disclosed |
| WO-2004089913-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | CA1 1919/4885CA2 442/4885CA9 1451/4885 |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | CA1 1551/4885CA2 3928/4885CA9 4809/4885 |
| US-20020193604-A1 | Aryl borates | BRD4, ABL1, BRD3 | CA1 3882/4885CA2 2090/4885CA9 643/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | CA1 4798/4885CA2 2673/4885CA9 2036/4885 |
| US-20020032339-A1 | ARYL BORATES | TBCB, HAT1, UBE2B | CA1 3496/4885CA2 2022/4885CA9 407/4885 |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | PRKAG1, PRKAG3, PRKAG2 | CA1 4878/4885CA2 4106/4885CA9 4721/4885 |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | CA1 4804/4885CA2 3873/4885CA9 3907/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | CA1 3271/4885CA2 2507/4885CA9 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.